Response to DAA therapy in the NHS England early access programme for rare HCV subtypes from low and middle income countries

da Silva Filipe, A. et al. (2017) Response to DAA therapy in the NHS England early access programme for rare HCV subtypes from low and middle income countries. Journal of Hepatology, 67(6), pp. 1348-1350. (doi:10.1016/j.jhep.2017.06.035) (PMID:28789880)

da Silva Filipe, A. et al. (2017) Response to DAA therapy in the NHS England early access programme for rare HCV subtypes from low and middle income countries. Journal of Hepatology, 67(6), pp. 1348-1350. (doi:10.1016/j.jhep.2017.06.035) (PMID:28789880)

[img]
Preview
Text
146263.pdf - Accepted Version

550kB

Abstract

No abstract available.

Item Type:Articles (Letter)
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Aranday-Cortes, Dr Elihu and Da Silva Filipe, Dr Ana and Hughes, Dr Joseph and Vattipally, Dr Sreenu and Thomson, Dr Emma and McLauchlan, Professor John
Authors: da Silva Filipe, A., Sreenu, V., Hughes, J., Aranday-Cortes, E., Irving, W. L., Foster, G. R., Agarwal, K., Rosenberg, W., Macdonald, D., Richardson, P., Aldersley, M. A., Wiselka, M., Ustianowski, A., McLauchlan, J., and Thomson, E. C.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Journal of Hepatology
Publisher:Elsevier
ISSN:0168-8278
ISSN (Online):1600-0641
Published Online:05 August 2017
Copyright Holders:Copyright © 2017 Crown Copyright
First Published:First published in Journal of Hepatology 67(6): 1348-1350
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
656341Virus-host interactions in hepatitis C virus infectionJohn McLauchlanMedical Research Council (MRC)MC_UU_12014/1MVLS III - CENTRE FOR VIRUS RESEARCH
645101T-cell mediated evolution of hepatitis C virus during acute infectionEmma ThomsonWellcome Trust (WELLCOTR)102789/Z/13/ZMVLS III - CENTRE FOR VIRUS RESEARCH